Recruiting

Trial ID CA127-1070 | NCT06352528

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

About This Trial
Key Eligibility Criteria
Trial Site Locations

Contact us for help
855-907-3286

Summary

Phase 1
18-75

Age Range
3

Locations
Recruiting

Overview

The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

:

Inclusion Criteria for all Participants (Group 1, Group 2, Group 3):.
1. Adult female (as assigned at birth) not of childbearing potential or male (as assigned at birth) of any race or ethnicity.
2. Must have a body mass index between 18 and 40 kg/m2 (inclusive) and body weight ≥ 50 kg at the time of signing the ICF.
Inclusion Criteria for Participants with Moderate or Severe Hepatic Impairment (Group 1 and Group 2):.
1. Participants have moderate or severe HI or cirrhosis due to chronic hepatic disease and/or prior alcohol use.
2. Participants have moderate (Group 1), or severe (Group 2) HI as defined by Child-Pugh score.
Inclusion Criteria for a Matched Healthy Participant (Group 3):.
1. Participant must be free of any clinically significant disease that would interfere with the study evaluations.
2. Participant must have liver-related laboratory test results within the respective reference ranges or with clinically insignificant excursions therefrom as agreed by the investigator.
3. Participant must be in good health as determined by past medical history, physical examination, vital signs, ECG, and clinical laboratory safety tests. Clinical laboratory safety tests (eg, hematology, chemistry, and urinalysis) and 12-lead ECGs must be within normal limits or clinically acceptable as judged by the investigator.

Exclusion Criteria

:

Exclusion Criteria for all Participants (Group 1, Group 2, and Group 3):.
1. Any major surgery within 4 weeks of the study intervention administration.
2. History of drug abuse within 1 year of study intervention administration.
3. History of alcohol abuse within 1 year of study intervention administration.
4. Participants who currently smoke, as well as those who have stopped smoking less than 6 months prior to dosing on Day 1.

Additional Information *

Other protocol-defined Inclusion/Exclusion criteria apply.

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Study Arms

Experimental: Group 1: Moderate Hepatic Impairment

ASSIGNED INTERVENTION

Drug: Repotrectinib

Study Arms

Experimental: Group 2: Severe Hepatic Impairment

ASSIGNED INTERVENTION

Drug: Repotrectinib

Study Arms

Experimental: Group 3: Normal Hepatic Function

ASSIGNED INTERVENTION

Drug: Repotrectinib

Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility

Check Your Eligibility

Answer some questions about Your health to see if you may match to this trial

Match to a Trial

If you are a match, click on the study to see the list of study site locations

Select a Study Site Location

Select a study site location that is convenient for you

Register

Provide your contact details for the study site to connect with you.